Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. The Company has developed a proprietary technology that is designed to deliver a drug that is retained in the ear for an extended period of time following a single local administration. Utilizing this technology, Otonomy has advanced multiple product candidates into development and launched its first product, OTIPRIO®.
OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement.
Type | Public | |
Founded | 2008 | |
HQ | San Diego, CA, US | Map |
Website | otonomy.com |
USD | |
---|---|
Revenue (Q3, 2020) | 50.0k |
Gross profit (Q3, 2020) | (139.0k) |
Gross profit margin (Q3, 2020), % | (278%) |
Net income (Q3, 2020) | (10.9m) |
EBIT (Q3, 2020) | (10.5m) |
Market capitalization (15-Jan-2021) | 250.8m |
Closing stock price (15-Jan-2021) | 5.2 |
Cash (30-Sept-2020) | 54.2m |
EV | 214.9m |
USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 358.0k | 326.0k | 282.0k | 301.0k | 123.0k | 113.0k | 192.0k | 190.0k | 125.0k | 160.0k | 10.0k | 50.0k |
Cost of goods sold | 463.0k | 397.0k | 290.0k | 272.0k | 241.0k | 162.0k | 213.0k | 203.0k | 220.0k | 214.0k | 511.0k | 189.0k |
Gross profit | (105.0k) | (71.0k) | (8.0k) | 29.0k | (118.0k) | (49.0k) | (21.0k) | (13.0k) | (95.0k) | (54.0k) | (501.0k) | (139.0k) |
Gross profit Margin, % | (29%) | (22%) | (3%) | 10% | (96%) | (43%) | (11%) | (7%) | (76%) | (34%) | (5010%) | (278%) |
USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (27.1m) | (71.3m) | (11.4m) | (25.0m) | (37.5m) | (12.0m) | (23.7m) | (33.7m) | (11.8m) | (23.2m) | (34.1m) | |
Depreciation and Amortization | 923.0k | 295.0k | 594.0k | 892.0k | 276.0k | 565.0k | 854.0k | 286.0k | 569.0k | 843.0k | ||
Inventories | 1.2m | 1.2m | 197.0k | 6.0k | ||||||||
Accounts Payable | 212.0k | 1.3m | 138.0k | 1.5m | (184.0k) | 321.0k | 123.0k | 837.0k | (90.0k) | (264.0k) | (491.0k) | (655.0k) |
USD | FY, 2016 |
---|---|
Revenue/Employee | 4.9k |
Financial Leverage | 1.1 x |
FY, 2016 | |
---|---|
Patents Issued | 88 |
Patents Pending | 115 |
Phase III Trials Products | 2 |
Products | 1 |
Otonomy has 214 Twitter Followers. The number of followers has decreased 2.6% month over month and decreased 3.5% quarter over quarter
When was Otonomy founded?
Otonomy was founded in 2008.
Who are Otonomy key executives?
Otonomy's key executives are David A. Weber, Carla da Luz Boren and Julie D. Burgess.
How many employees does Otonomy have?
Otonomy has 49 employees.
What is Otonomy revenue?
Latest Otonomy annual revenue is $600 k.
What is Otonomy revenue per employee?
Latest Otonomy revenue per employee is $12.2 k.
Who are Otonomy competitors?
Competitors of Otonomy include Seed Health, BeyondSpring and GT Biopharma.
Where is Otonomy headquarters?
Otonomy headquarters is located at 4796 Executive Dr, San Diego.
Where are Otonomy offices?
Otonomy has an office in San Diego.
How many offices does Otonomy have?
Otonomy has 1 office.
Receive alerts for 300+ data fields across thousands of companies